In this work we studied the effects on MM cell‐lines of two classes of bromodomain (BET and CBP/Ep300) inhibitors, with putatively distinct transcriptional effects, with the aim to disrupt the oncogenic feedback loop between MYC and IRF4. The gene discussed is DNER; the disease is Miyoshi myopathy.